Table 1

Baseline characteristics of participants

Patient characteristics
(n=70)
Total (%)
N=70
ESPB (%)
N=35
Intravenous morphine (%)
N=35
P value
Sex0.179
 Male51 (72.9%)28 (54.9%)23 (45.1%)
 Female19 (27.1%)7 (36.8%)12 (63.2%)
Age (years)0.950
 18–3019 (27.1%)11 (31.4%)8 (22.9%)
 31–4019 (27.1%)7 (20%)12 (34.3%)
 41–5014 (20%)8 (22.9%)6 (17.1%)
 51–6013 (18.6%)6 (17.1%)7 (20%)
 61–705 (7.2%)3 (8.6%)2 (5.7%)
Comorbidities
 Diabetes23 (32.9%)10 (28.6%)13 (37.1%)0.445
 Hypertension16 (45.7%)8 (22.6%)8 (22.9%)1.000
 Chronic liver disease1 (1.4%)1 (2.9%)01.000
 Coronary artery disease2 (2.9%)1 (2.9%)1 (2.9%)1.000
 Reactive airway disease2 (2.9%)1 (2.9%)1 (2.9%)1.000
 Chronic smoking11 (15.7%)8 (22.9%)3 (8.6%)0.188
 Chronic alcohol consumption26 (37.1%)15 (42.9%)11 (31.4%)0.322
Diagnoses
 Acute pancreatitis38 (54.3%)18 (51.4%)20 (57.1%)0.952
 Acute on chronic pancreatitis19 (27.1%)11 (31.4%)8 (22.9%)
 Chronic pancreatitis7 (10%)3 (8.6%)4 (11.4%)
 Cholangiocarcinoma4 (5.7%)2 (5.7%)2 (5.7%)
 Cholecystitis2 (2.9)1 (2.9%)1 (2.9%)
Severity of pancreatitis (Atlanta)
 Mild28 (40%)13 (37.1%)15 (42.9%)0.636
 Moderate21 (30%)13 (37.1%)8 (22.9%)
 Severe8 (11.4%)3 (8.6%)5 (14.3%)
 Not applicable13 (18.6%)6 (17.2%)7 (20%)
  • ESPB, erector-spinae plane block.